- Alnylam's stock is down 30% despite a booming biotech market. Here's whyAlnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A is up, IPOs are back with record-breaking force a…
- Mirae raises $5.4M to turn patient texts into data for doctorsAs people increasingly turn to AI chatbots for health questions, one startup wants patients to talk to its chatbot about their symptoms, so their doctors can make better treatment decisions. Mirae,…